Ventracor eyes 2007 EU LVAD (left ventricular assist device) nod:
This article was originally published in Clinica
Ventracor believes it is on course to CE-marking for sale in Europe early next year its VentrAssist heart pump, following positive data from its bridge-to-transplant clinical trial. The left ventricular assist device (LVAD) showed an 83% success rate - significantly better than earlier published results of first generation devices - and the adverse event rate was in line with expectations, said the company. The results were presented at the European Association of Cardiothoracic Surgeons' annual meeting in Sweden this month. VentrAssist is a third generation centrifugal implantable blood pump designed for long-term use in patients with advanced heart failure. The pump has no wearing parts and is lightweight and small, enabling it to be used in both children and adults.